Remdesivir

What To Know About Rand Paul Failing To Disclose Gilead Stock Purchase For 16 Months
NanoViricides Jumps On 'Strong Pan-Coronavirus Effectiveness' From 2 COVID-19 Candidates In Lab Studies
Gilead CEO: We Expect Remdesivir To Work On New COVID-19 Strains
NanoViricides Jumps On 'Strong Pan-Coronavirus Effectiveness' From 2 COVID-19 Candidates In Lab Studies
Gilead CEO: We Expect Remdesivir To Work On New COVID-19 Strains
Eli Lilly's Arthritis Drug Gets Emergency Use Approval For Treatment Of COVID-19
WHO Advises Against Gilead's Remdesivir For COVID-19 Despite FDA Approval

Remdesivir Recent News

FDA Approves Gilead's Remdesivir For Treatment Of Hospitalized COVID-19 Patients
The U.S. Food and Drug Administration has approved the antiviral Veklury, commonly known as remdesivir, for the treatment of hospitalized patients with COVID-19.
Gilead's Remdesivir Ineffective In COVID-19 Patients, WHO Study Finds
Gilead Sciences, Inc.'s (NASDAQ: GILD) antiviral drug remdesivir has been found to ha
Eli Lilly Halts Antibody COVID-19 Trial
In the race to get COVID-19 treatment options to market, Eli Lilly is the latest to suffer a setback.
Gilead's Veklury Study Shows Faster COVID-19 Recovery, Reduced Disease Progression, Mortality
Gilead Sciences, Inc.
Ligand: The Small Cap Powering Gilead's Remdesivir
President Donald Trump has taken several treatments to combat the coronavirus diagnosis he received last week.
Trump To Depart Walter Reed, Says 'Don't Be Afraid' Of COVID-19 As Virus-Related Death Toll Nears 210K In US
President Donald Trump was taken to the Walter Reed Medical Center on Friday to treat his coronavirus diagnosis.
PreMarket Prep Stock Of The Day: Gilead Sciences
Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session.
Trump's Doc Says President Fever-Free, Taking COVID-19 Treatment Remdesivir At Walter Reed
President Donald Trump is “doing very well” at Walter Reed National Military Medical Center following his coronavirus diagnosis and
Gilead, Pfizer, Eli Lilly CEOs On COVID-19 Treatments, Vaccine Development
Major coronavirus treatments and vaccine maker executives were interviewed on CNBC Monday to discuss their company's progress in the battle against the disease.
Gilead Seeks Full FDA Approval Of Its Remdesivir Drug For Coronavirus
Gilead Sciences, Inc (NASDAQ: GILD) announced Monday it was seeking complete Food and Drug Administr
Pfizer, Gilead Strike Multiyear Partnership To Manufacture COVID-19 Drug Remdesivir
Large-cap biopharma companies Pfizer Inc. (NYSE: PFE) and Gilead Sciences, Inc.
Gilead Analysts Downplay Q2 Miss Amid Remdesivir's COVID-19 Opportunity
Gilead Sciences, Inc. (NASDAQ: GILD) reported second-quarter revenues and earnings that trailed expectations. The Gilead Analysts
Ex-FDA Commissioner Gottlieb On Whether Coronavirus Vaccine Will Bring Return To Normal
Many investors are working under the assumption that a safe vaccine against the coronavirus will allow society to return to how it was pre-pandemic. Investors may be missing part of the story, including how the vaccines work, former FDA Commissioner Dr. Scott Gottlieb said on CNBC's "Squawk Box."
Credit Suisse Upgrades Gilead On Remdesivir Commercial Opportunity
The biotech sector is a surefire winner due to a two-pronged benefit from the coronavirus pandemic, according to an analyst at Credit Suisse. 
BofA On 3 Coronavirus Vaccine Frontrunners, The Remdesivir Opportunity And Antibodies
The markets are ready for a steady flow of updates from COVID-19 drug and vaccine developers as the world races to contain the pandemic and bring back some semblance of normalcy. Against this backdrp, BofA Securities issued an update to its view on COVID-19 market opportunities.
Gilead's Remdesivir Data Shows Improved Clinical Recovery, Reduced Death Rate
Gilead Sciences, Inc.
Gilead Announces Pricing Of Coronavirus Treatment Remdesivir: 'We Believe All Patients Will Have Access'
Gilead Sciences, Inc. (NASDAQ: GILD) announced pricing Monday for its antiviral remdesivir, which has been granted  emergency use authorization by the FDA for treating COVID-19.
FDA Withdraws Emergency Use Authorization For Hydroxychloroquine
The United States Food and Drug Administration on Monday withdrew the emergency use authorization it granted for hydroxychloroquine and chloroquine sulfates against the COVID-19 coronavirus.
Here's How Large Option Traders Are Playing Gilead Following Latest COVID-19 Trial Data
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) traded lower by 4% on Thursday amid broad market weakness following a spike in U.S. coronavirus cases.
Gilead Analyst: Coronavirus Drug, Arcus Collaboration Make Biopharma A Buy
The consensus estimates for Gilead Sciences, Inc. (NASDAQ: GILD) appear overly conservative, especially given the prospects of remdesivir and products from the company’s recent collaboration with Arcus Biosciences Inc (NYSE:
Pharma Large And Mid-Caps Race Against COVID-19
COVID-19 coronavirus made us realize that health should always be our top priority. Here are some companies working to make the world a better place after the pandemic. 
Gilead Falls On Mixed Results From Late-Stage Remdesivir Study In Moderate COVID-19
Gilead Sciences, Inc. (NASDAQ: GILD) shares have come under selling pressure after the company released results from a Phase 3 study of its COVID-19 treatment candidate remdesivir.
UK Clears Gilead's Remdesivir For Some Coronavirus Patients
The U.K. approved the use Tuesday of Gilead Sciences Inc's (NASDAQ: GILD) remdesivir for some patients with COVID-19. 

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved